In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...

Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it | ...

The findings suggest that the HER2DX assay could help clinicians decide on the appropriate use of chemotherapy in older patients, study researchers wrote.

The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...

In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025—a global assessment ...

Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs.

The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 - a landmark global ...

Around 900 people with high-risk early-stage (N2) breast cancer would be expected to benefit from this treatment in the first five years if funding were approved.

Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat using standard therapies. But with early detection, the right treatment ...